APLM
Apollomics Inc
$
18.433
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
18.4331
Open
18.4331
VWAP
--
Vol
--
Mkt Cap
22.85M
Low
18.4331
Amount
--
EV/EBITDA(TTM)
--
Total Shares
109.73M
EV
11.54M
EV/OCF(TTM)
--
P/S(TTM)
--
Apollomics Inc. is a clinical-stage biopharmaceutical company focusing on discovering and developing oncology therapies to address unmet medical needs, especially for difficult-to-treat and treatment-resistant cancers. The product candidates in its pipeline are categorized into two groups based on their mechanisms of action, each of which contains product candidates at different stages of development: tumor inhibitors and immuno-oncology drugs. Its tumor inhibitor product candidates consist of three small-molecule inhibitors against different uncontrolled growth signaling pathways in cancer cells: vebreltinib, APL-102 and APL-122. Its three immuno-oncology product candidates consist of APL-501, APL-502 and APL-80. Vebreltinib is a potent, oral active selective c-Met inhibitor. APL-102 is an oral active, small molecule Multiple Tyrosine Kinase Inhibitor. APL-122 is a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways. APL-501 is an anti-PD-1 antibody product candidate.
Show More
Valuation Metrics
The current forward P/E ratio for Apollomics Inc (APLM.O) is -0.21, compared to its 5-year average forward P/E of -4.57. For a more detailed relative valuation and DCF analysis to assess Apollomics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.57
Current PE
-0.21
Overvalued PE
1.33
Undervalued PE
-10.47
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-4.01
Current EV/EBITDA
-0.23
Overvalued EV/EBITDA
2.08
Undervalued EV/EBITDA
-10.09
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
31.41
Current PS
26.14
Overvalued PS
148.98
Undervalued PS
-86.16
Financials
Annual
Quarterly
FY2022Q4
N/A
Total Revenue
FY2022Q4
YoY :
+132.81%
-418.45K
Operating Profit
FY2022Q4
YoY :
-84.92%
-25.88K
Net Income after Tax
FY2022Q4
YoY :
-100.00%
0.00
EPS - Diluted
FY2022Q4
YoY :
-100.00%
N/A
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
APLM News & Events
Events Timeline
2025-09-17 (ET)
2025-09-17
17:51:15
Nasdaq Suspends Trading of Apollomics
2025-03-31 (ET)
2025-03-31
08:21:54
Apollomics, LaunXP enter development, commercial agreement for Vebreltinib
2024-12-20 (ET)
2024-12-20
07:04:35
Apollomics announces results from Phase 3 bridging trial of uproleselan
Sign Up For More Events
Sign Up For More Events
News
2.0
09-17GlobenewswireNasdaq Suspends Trading of Apollomics Inc., Ltd.
2.0
05-21NASDAQ.COMWhat's Behind The Big Stock Moves? BDSX, APLM, RNAZ...
9.5
04-03NewsfilterApollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
Sign Up For More News
People Also Watch
MHUA
Meihua International Medical Technologies Co Ltd
0.392
USD
-2.00%
BIAF
bioAffinity Technologies Inc
5.170
USD
+3.82%
HOTH
Hoth Therapeutics Inc
1.940
USD
+7.78%
SQFT
Presidio Property Trust Inc
6.070
USD
-8.03%
RVYL
Ryvyl Inc
0.293
USD
-2.33%
ICU
SeaStar Medical Holding Corp
1.000
USD
+10.87%
XELB
Xcel Brands Inc
1.550
USD
+11.51%
GVH
Globavend Holdings Ltd
5.030
USD
-2.61%
FAQ
What is Apollomics Inc (APLM) stock price today?
The current price of APLM is 18.4331 USD — it has increased 33.92 % in the last trading day.
What is Apollomics Inc (APLM)'s business?
What is the price predicton of APLM Stock?
What is Apollomics Inc (APLM)'s revenue for the last quarter?
What is Apollomics Inc (APLM)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Apollomics Inc (APLM)'s fundamentals?
How many employees does Apollomics Inc (APLM). have?